Results 31 to 40 of about 279,790 (190)
Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
Frontiers in Immunology, 2022 The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies.
Feifei Nan +9 more
doaj +1 more source
TGF-β-responsive CAR-T cells promote anti-tumor immune function. [PDF]
, 2018 A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-β) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant.
Chang, ZeNan L +4 more
core +1 more source
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited.
Van To +11 more
doaj +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
Optimizing CAR T cell therapy in lymphoma [PDF]
Hematological Oncology, 2021 AbstractChimeric antigen receptor (CAR) T cell therapy has significantly improved the outlook for patients with certain types of poor‐risk lymphoma. Despite these advances, a majority of patients undergoing CAR T therapy will suffer progression or relapse of disease, and toxicity remains a concern.
David Qualls, Gilles Salles
openaire +2 more sources
CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
Journal of Immunology Research, 2020 Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. Like other technologies, CAR-T cell therapy has undergone a long development process, and persistent explorations of the ...
Qingyang Zhang +7 more
doaj +1 more source
Nanobody based dual specific CARs [PDF]
, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +2 more sources
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Frontiers in Immunology, 2023 Patient-derived autologous chimeric antigen receptor (CAR)-T cell therapy is a revolutionary breakthrough in immunotherapy and has made impressive progress in both preclinical and clinical studies.
Zixin Lv +5 more
doaj +1 more source
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of certain hematological malignancies. While CAR-T cells have produced robust responses in certain hematological malignancies, toxicities associated with the therapy ...
Robert C. Sterner, Rosalie M. Sterner
doaj +1 more source
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia [PDF]
, 2015 Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose limiting toxicities.
Anne Angiolillo +2 more
core +3 more sources